Insect Cell Culture Media Patents: Top Companies & Trends 2026
Insect Cell Culture Media Formulation Patents: Who Holds the Claims
28.1% concentration at the top. The five leading assignees hold 852 of 3,032 records in scope, but that still leaves a long tail of single- and few-filing entrants below tenth place. Annual filings rose to a peak of 88 in 2021 before declining to 42 by 2024, a -52% move over that three-year span. 2025 and 2026 counts are still climbing as publications catch up to filing dates roughly 18 months behind, so the apparent recent drop should not be read as the field slowing down yet.
- 1HUMAN GENOME SCI INC17.0%
- 2MEDICAGO INC3.6%
- 3IMMUNEX CORP2.8%
- 4RGT UNIV OF CALIFORNIA2.4%
- 5THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES2.3%
See the full insect cell culture media formulation analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions
Who holds the most patents in insect cell culture media formulation?
The dataset ranks 100 assignees by patent family count, with the leading company holding 516 of the 3,032 records in scope. The top five combined hold 852 records, or 28.1% of the total, which is a meaningful concentration but far from a monopoly — the remaining 71.9% is spread across the other 95 ranked companies plus unranked filers. Anyone assessing competitive risk should look at both the leader’s portfolio and the mid-table cluster around fifth to tenth place, since volumes there (70 and 58 records respectively) are still substantial.
Is patent filing in this field growing or shrinking?
Filings peaked at 88 in 2021 and fell to 42 by 2024, a -52% move over that three-year span, which is the most recent period that can be treated as complete. Because patent publication typically lags actual filing by around 18 months, the 2025 and 2026 figures in any chart are still incomplete and will rise as more applications publish. The honest read is a cooling from a 2021 high, not a confirmed downward trend into the present.
What does it mean that C12N appears on 93.2% of records?
It means nearly all records in this scope are classified under microorganisms and genetic engineering (C12N), not that the field is purely about that subject — records commonly carry several IPC classes at once, which is why C12N, C07K (73.4%) and A61K (71.6%) all appear on large, overlapping shares of the same 3,032 records. In practice this tells you that insect cell media formulation claims are usually embedded inside broader recombinant protein or biologics production filings rather than filed as standalone media patents.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Insect Cell Culture Media Formulation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.